TransCode Therapeutics (NASDAQ:RNAZ) Announces Quarterly Earnings Results

TransCode Therapeutics (NASDAQ:RNAZ) released its quarterly earnings data on Friday. The company reported ($7.17) EPS for the quarter, FiscalAI reports.

TransCode Therapeutics Trading Down 5.7%

RNAZ stock traded down $0.20 during mid-day trading on Friday, hitting $3.28. 40,808 shares of the company were exchanged, compared to its average volume of 17,396. The firm has a fifty day simple moving average of $6.00 and a 200 day simple moving average of $7.64. The company has a market capitalization of $3.48 million, a PE ratio of -0.07 and a beta of 1.24. TransCode Therapeutics has a twelve month low of $3.21 and a twelve month high of $20.99.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TransCode Therapeutics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, TransCode Therapeutics currently has an average rating of “Sell”.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.